Spyre Begin Period Cash Flow vs Change To Account Receivables Analysis

SYRE Stock

26.44 0.05 0.19%

Spyre Therapeutics financial indicator trend analysis is much more than just breaking down Spyre Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spyre Therapeutics is a good investment. Please check the relationship between Spyre Therapeutics Begin Period Cash Flow and its Change To Account Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

Begin Period Cash Flow vs Change To Account Receivables

Begin Period Cash Flow vs Change To Account Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spyre Therapeutics Begin Period Cash Flow account and Change To Account Receivables. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Spyre Therapeutics' Begin Period Cash Flow and Change To Account Receivables is -0.36. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change To Account Receivables in the same time period over historical financial statements of Spyre Therapeutics, assuming nothing else is changed. The correlation between historical values of Spyre Therapeutics' Begin Period Cash Flow and Change To Account Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Spyre Therapeutics are associated (or correlated) with its Change To Account Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Account Receivables has no effect on the direction of Begin Period Cash Flow i.e., Spyre Therapeutics' Begin Period Cash Flow and Change To Account Receivables go up and down completely randomly.

Correlation Coefficient

-0.36

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Change To Account Receivables

Most indicators from Spyre Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 77.9 M, whereas Tax Provision is projected to grow to (24.7 K).

	2021	2022	2023	2024 (projected)
Interest Income	111K	837K	6.1M	6.5M
Net Interest Income	111K	837K	6.1M	6.5M

Interest Income Net Interest Income

Spyre Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Capital Lease Obligations	Net Invested Capital
Total Assets		0.87	0.73	0.79	-0.08	-0.01	-0.79	-0.91	0.29	0.95	-0.06	-0.15	-0.92	1.0	-0.49	0.94	0.95	0.97	0.19	0.91	0.98	1.0	0.91	0.97	-0.95	-0.56
Other Current Liab	0.87		0.78	0.53	-0.06	-0.03	-0.45	-0.92	0.37	0.74	-0.02	0.06	-0.86	0.86	-0.52	0.93	0.92	0.91	0.34	0.89	0.93	0.86	0.89	0.9	-0.92	-0.75
Total Current Liabilities	0.73	0.78		0.77	0.43	0.32	-0.35	-0.87	0.66	0.55	0.46	0.27	-0.49	0.7	-0.55	0.81	0.82	0.67	0.52	0.86	0.73	0.71	0.85	0.63	-0.64	-0.26
Total Stockholder Equity	0.79	0.53	0.77		0.14	0.18	-0.75	-0.7	0.3	0.75	0.14	-0.13	-0.49	0.78	-0.42	0.69	0.73	0.68	0.11	0.71	0.7	0.78	0.7	0.67	-0.64	-0.13
Property Plant And Equipment Net	-0.08	-0.06	0.43	0.14		0.57	0.25	-0.16	0.79	-0.25	1.0	0.6	0.28	-0.13	-0.23	0.06	0.02	-0.25	0.72	0.23	-0.15	-0.13	0.2	-0.3	0.31	0.63
Current Deferred Revenue	-0.01	-0.03	0.32	0.18	0.57		0.14	-0.01	0.58	-0.15	0.53	-0.1	0.17	-0.03	-0.32	-0.05	0.11	-0.16	0.11	0.06	-0.09	-0.04	0.04	-0.18	0.22	0.47
Net Debt	-0.79	-0.45	-0.35	-0.75	0.25	0.14		0.59	0.12	-0.93	0.25	0.45	0.7	-0.81	0.39	-0.64	-0.58	-0.75	0.07	-0.59	-0.72	-0.8	-0.59	-0.76	0.72	0.33
Retained Earnings	-0.91	-0.92	-0.87	-0.7	-0.16	-0.01	0.59		-0.42	-0.8	-0.2	-0.2	0.81	-0.89	0.57	-0.99	-0.91	-0.89	-0.54	-0.99	-0.93	-0.9	-0.99	-0.87	0.88	0.53
Accounts Payable	0.29	0.37	0.66	0.3	0.79	0.58	0.12	-0.42		0.04	0.8	0.41	-0.14	0.24	-0.32	0.35	0.47	0.16	0.55	0.47	0.25	0.25	0.45	0.11	-0.09	0.26
Cash	0.95	0.74	0.55	0.75	-0.25	-0.15	-0.93	-0.8	0.04		-0.24	-0.33	-0.9	0.96	-0.45	0.85	0.81	0.94	0.04	0.79	0.92	0.96	0.8	0.94	-0.92	-0.57
Non Current Assets Total	-0.06	-0.02	0.46	0.14	1.0	0.53	0.25	-0.2	0.8	-0.24		0.65	0.25	-0.11	-0.25	0.11	0.05	-0.21	0.76	0.27	-0.12	-0.1	0.24	-0.26	0.27	0.59
Non Currrent Assets Other	-0.15	0.06	0.27	-0.13	0.6	-0.1	0.45	-0.2	0.41	-0.33	0.65		0.21	-0.19	-0.07	0.13	-0.01	-0.18	0.83	0.22	-0.12	-0.18	0.21	-0.22	0.18	0.22
Other Assets	-0.92	-0.86	-0.49	-0.49	0.28	0.17	0.7	0.81	-0.14	-0.9	0.25	0.21		-0.93	0.39	-0.87	-0.87	-0.95	-0.13	-0.8	-0.94	-0.93	-0.81	-0.95	0.94	0.7
Cash And Short Term Investments	1.0	0.86	0.7	0.78	-0.13	-0.03	-0.81	-0.89	0.24	0.96	-0.11	-0.19	-0.93		-0.47	0.93	0.94	0.98	0.15	0.89	0.98	1.0	0.89	0.97	-0.96	-0.58
Net Receivables	-0.49	-0.52	-0.55	-0.42	-0.23	-0.32	0.39	0.57	-0.32	-0.45	-0.25	-0.07	0.39	-0.47		-0.55	-0.45	-0.44	-0.45	-0.59	-0.47	-0.47	-0.54	-0.41	0.42	0.23
Common Stock Shares Outstanding	0.94	0.93	0.81	0.69	0.06	-0.05	-0.64	-0.99	0.35	0.85	0.11	0.13	-0.87	0.93	-0.55		0.92	0.93	0.47	0.98	0.96	0.93	0.99	0.91	-0.92	-0.59
Short Term Investments	0.95	0.92	0.82	0.73	0.02	0.11	-0.58	-0.91	0.47	0.81	0.05	-0.01	-0.87	0.94	-0.45	0.92		0.92	0.26	0.91	0.95	0.94	0.91	0.91	-0.89	-0.53
Non Current Liabilities Total	0.97	0.91	0.67	0.68	-0.25	-0.16	-0.75	-0.89	0.16	0.94	-0.21	-0.18	-0.95	0.98	-0.44	0.93	0.92		0.13	0.87	0.99	0.98	0.88	1.0	-0.99	-0.73
Other Current Assets	0.19	0.34	0.52	0.11	0.72	0.11	0.07	-0.54	0.55	0.04	0.76	0.83	-0.13	0.15	-0.45	0.47	0.26	0.13		0.57	0.2	0.16	0.55	0.08	-0.11	0.11
Other Stockholder Equity	0.91	0.89	0.86	0.71	0.23	0.06	-0.59	-0.99	0.47	0.79	0.27	0.22	-0.8	0.89	-0.59	0.98	0.91	0.87	0.57		0.91	0.89	1.0	0.84	-0.84	-0.45
Total Liab	0.98	0.93	0.73	0.7	-0.15	-0.09	-0.72	-0.93	0.25	0.92	-0.12	-0.12	-0.94	0.98	-0.47	0.96	0.95	0.99	0.2	0.91		0.98	0.92	0.99	-0.98	-0.69
Total Current Assets	1.0	0.86	0.71	0.78	-0.13	-0.04	-0.8	-0.9	0.25	0.96	-0.1	-0.18	-0.93	1.0	-0.47	0.93	0.94	0.98	0.16	0.89	0.98		0.9	0.97	-0.96	-0.58
Common Stock	0.91	0.89	0.85	0.7	0.2	0.04	-0.59	-0.99	0.45	0.8	0.24	0.21	-0.81	0.89	-0.54	0.99	0.91	0.88	0.55	1.0	0.92	0.9		0.85	-0.86	-0.47
Short Long Term Debt Total	0.97	0.9	0.63	0.67	-0.3	-0.18	-0.76	-0.87	0.11	0.94	-0.26	-0.22	-0.95	0.97	-0.41	0.91	0.91	1.0	0.08	0.84	0.99	0.97	0.85		-1.0	-0.75
Capital Lease Obligations	-0.95	-0.92	-0.64	-0.64	0.31	0.22	0.72	0.88	-0.09	-0.92	0.27	0.18	0.94	-0.96	0.42	-0.92	-0.89	-0.99	-0.11	-0.84	-0.98	-0.96	-0.86	-1.0		0.79
Net Invested Capital	-0.56	-0.75	-0.26	-0.13	0.63	0.47	0.33	0.53	0.26	-0.57	0.59	0.22	0.7	-0.58	0.23	-0.59	-0.53	-0.73	0.11	-0.45	-0.69	-0.58	-0.47	-0.75	0.79

Click cells to compare fundamentals

Spyre Therapeutics Account Relationship Matchups

Spyre Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	83.2M	161.6M	109.9M	71.1M	341.9M	359.0M
Other Current Liab	14.8M	464K	14.0M	12.8M	31.1M	32.6M
Total Current Liabilities	18.4M	16.4M	20.1M	14.7M	32.0M	16.7M
Total Stockholder Equity	60.1M	139.8M	83.9M	50.3M	184.0M	96.1M
Property Plant And Equipment Net	1.0M	7.2M	9.9M	8.4M	6.7M	0.0
Net Debt	(14.1M)	(84.6M)	(10.1M)	(30.2M)	(104.3M)	(99.1M)
Retained Earnings	(195.1M)	(276.0M)	(341.8M)	(425.6M)	(764.4M)	(726.2M)
Accounts Payable	3.2M	2.3M	3.3M	677K	896K	1.6M
Cash	19.3M	90.1M	15.1M	34.9M	188.9M	198.3M
Non Current Assets Total	8.7M	11.8M	11.0M	8.9M	331K	314.5K
Non Currrent Assets Other	11K	115K	842K	683K	9K	8.6K
Cash And Short Term Investments	71.9M	146.3M	93.1M	55.7M	339.3M	356.2M
Net Receivables	3.1M	300K	815K	375K	337.5K	320.6K
Common Stock Shares Outstanding	1.3M	2.1M	2.6M	3.4M	6.9M	7.2M
Short Term Investments	52.7M	56.2M	78.0M	20.8M	150.4M	157.9M
Liabilities And Stockholders Equity	83.2M	161.6M	109.9M	71.1M	341.9M	359.0M
Non Current Liabilities Total	4.7M	5.3M	5.8M	6.2M	125.9M	132.2M
Other Current Assets	2.6M	3.5M	4.9M	6.2M	2.3M	3.4M
Other Stockholder Equity	255.1M	415.8M	425.8M	476.0M	763.2M	801.4M
Total Liab	23.1M	21.8M	26.0M	20.8M	157.8M	165.7M
Total Current Assets	74.5M	149.8M	98.9M	62.3M	341.5M	358.6M
Accumulated Other Comprehensive Income	51K	11K	(20K)	(48K)	302K	317.1K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:

How To Invest In Spyre

Details

Is Spyre Stock a good investment?

Details

What is Spyre Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(37.90)

Return On Assets

(0.39)

Return On Equity

(0.92)

The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Spyre Begin Period Cash Flow vs Change To Account Receivables Analysis

Begin Period Cash Flow vs Change To Account Receivables

Begin Period Cash Flow vs Change To Account Receivables Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Change To Account Receivables

Spyre Therapeutics fundamental ratios Correlations

Spyre Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Spyre Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Other Stockholder Equity

Capital Lease Obligations	- 1.0	Short Long Term Debt Total
Capital Lease Obligations	- 0.99	Non Current Liabilities Total
Common Stock	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.99	Retained Earnings
Capital Lease Obligations	- 0.98	Total Liab